Low-dose buprenorphine to prevent remifentanil-induced hyperalgesia after major lung resection: a prospective, randomised, controlled, double-blinded study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN91017061

Enrollment

Registered

2008-12-11

Start date

2008-04-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-operative remifentanil-induced hyperalgesia Skin and Connective Tissue Diseases Disturbances of skin sensation

Interventions

All patients will receive remifentanil based general anaesthesia (target-controlled infusion [TCI] system), supplemented with oxygen and desflurane. Patients will then be randomised to: 1. Buprenorphi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Adult patients (American Society of Anaesthesiologists [ASA] grade I - III) undergoing major lung resections 2. Aged greater than 18 years, either sex

Exclusion criteria

Exclusion criteria: 1. Extremely high or low weight (less than 40 kg and greater than 100 kg) 2. Known abuse of opioid drugs 3. Patients unable to manage a patient-controlled analgesia (PCA) device

Design outcomes

Primary

Measure	Time frame
Post-operative morphine consumption (PCA).	—

Secondary

Measure	Time frame
1. Morphine titration at the end of the surgery 2. Visual Analogue Scale (VAS) at rest and during coughing at 24 and 48 hours 3. Hyperalgesic area at 24 and 48 hours (Quantitative Sensory Testing) 4. Length of post-operative hospitalisation 5. Incidence of post-thoracotomy pain after one month from surgery	—

Countries

Italy

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026